128 signals · bluesky, h1b_lca, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Elevated risk signals — operational or reputational pressure patterns observed.
Auto-generated from public signals — AI summary pending. Based on 4 recent signals.
2) We cannot litigate our way through drug pricing. If pharma loses one lawsuit, they will file another. Amgen sued Colorado in 2024 but a judge dismissed the case. They sued again in 2025, and this time a judge blocked the price cap.
If pharma loses one lawsuit, they will file another.
Biotechnology company focused on human biology.
Based on 128 signals across 3 sources · snapshot 12 Jul 2026
Strong — enough signals from diverse sources to trust this score.
Overall community sentiment for Amgen is mixed based on public signals as of 12 Jul 2026.
Based on 128 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
Amgen Inc. Stock 12‑Month Price Target Raised to $355.04, Implies 5% Downside TradingView
Stock 12‑Month Price Target Raised to $355.04, Implies 5% Downside TradingView